iTeos Therapeutics, Inc.
NASDAQ:ITOS
Overview | Financials
| Company Name | iTeos Therapeutics, Inc. |
| Symbol | ITOS |
| Currency | USD |
| Price | 10.15 |
| Market Cap | 448,684,810 |
| Dividend Yield | 0% |
| 52-week-range | 4.8 - 17.63 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Michel Detheux Ph.D. |
| Website | https://www.iteostherapeutics.com |
An error occurred while fetching data.
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD






